Observational studyBlood advances2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Silvia Bonfiglio et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
46 papers cite it
this paperpooled ittrialcites it